Loading...
XSTO
VITR
Market cap2.16bUSD
Apr 14, Last price  
155.50SEK
1D
2.37%
1Q
-24.07%
Jan 2017
100.90%
Name

Vitrolife AB

Chart & Performance

D1W1MN
P/E
41.05
P/S
5.83
EPS
3.79
Div Yield, %
0.64%
Shrs. gr., 5y
4.55%
Rev. gr., 5y
19.51%
Revenues
3.61b
+2.76%
120,120,000171,264,000188,939,000225,141,000274,626,000297,565,000356,115,000362,020,000452,738,000510,512,000722,370,000856,106,0001,046,217,0001,151,348,0001,480,132,0001,245,572,0001,680,804,0003,234,000,0003,512,000,0003,609,000,000
Net income
513m
P
14,859,00015,199,00036,057,00029,995,00034,114,00029,182,00030,360,000333,772,00056,274,000109,109,000182,845,000190,368,000263,640,000309,697,000382,785,000286,845,000341,000,000394,000,000-3,851,000,000513,000,000
CFO
907m
+19.82%
14,121,00023,784,00021,285,00042,793,00041,478,00048,399,00039,460,00059,930,000106,127,000145,666,000193,526,000181,262,000312,189,000349,435,000413,333,000356,448,000384,306,000636,000,000757,000,000907,000,000
Dividend
Apr 30, 20251.1 SEK/sh
Earnings
Apr 16, 2025

Profile

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.
URL
https://www.vitrolife.com/
IPO date
Jun 26, 2001
Employees
1,102
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,609,000
2.76%
3,512,000
8.60%
3,234,000
92.41%
Cost of revenue
2,819,000
2,879,000
2,599,000
Unusual Expense (Income)
NOPBT
790,000
633,000
635,000
NOPBT Margin
21.89%
18.02%
19.64%
Operating Taxes
160,000
139,000
143,000
Tax Rate
20.25%
21.96%
22.52%
NOPAT
630,000
494,000
492,000
Net income
513,000
-113.32%
(3,851,000)
-1,077.41%
394,000
15.54%
Dividends
(135,000)
(115,000)
(109,000)
Dividend yield
0.46%
0.44%
0.43%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
160,000
147,000
182,000
Long-term debt
2,066,000
2,042,000
2,127,000
Deferred revenue
Other long-term liabilities
115,000
72,000
45,000
Net debt
1,091,000
1,269,000
1,695,000
Cash flow
Cash from operating activities
907,000
757,000
636,000
CAPEX
(67,000)
(87,000)
Cash from investing activities
(377,000)
(124,000)
(144,000)
Cash from financing activities
(286,000)
(300,000)
(582,000)
FCF
510,000
356,000
229,828
Balance
Cash
1,135,000
861,000
578,000
Long term investments
59,000
36,000
Excess cash
954,550
744,400
452,300
Stockholders' equity
(1,578,000)
(821,000)
3,196,000
Invested Capital
17,423,000
15,705,000
18,530,700
ROIC
3.80%
2.89%
2.75%
ROCE
4.67%
3.98%
3.16%
EV
Common stock shares outstanding
135,566
135,395
135,395
Price
215.00
10.43%
194.70
4.56%
186.20
-66.75%
Market cap
29,146,690
10.57%
26,361,333
4.56%
25,210,478
-60.73%
EV
30,239,690
27,631,333
26,909,478
EBITDA
790,000
1,058,000
1,031,000
EV/EBITDA
38.28
26.12
26.10
Interest
94,000
44,000
Interest/NOPBT
14.85%
6.93%